@CGT_Live CGTLive®

CGTLive® posts on X about data, gene, in the, icymi the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

Mentions: [--] #

Followers: [---] #

CreatorRank: undefined #

Social Influence

Social category influence stocks countries finance technology brands travel destinations currencies

Social topic influence data, gene, in the, icymi, events, the first, cart, type, phd, novartis

Top assets mentioned Novartis AG (NVS) Passage Bio, Inc. (PASG) Gracell Biotechnologies Inc. (GRCL) AbbVie Inc (ABBV) Pfizer, Inc. (PFE) Serum (SRM) Sanofi (SNY) SQZ Biotechnologies Co (SQZ) Lexeo Therapeutics, Inc (LXEO) Frontier (FRONT) Mantle (MNT)

Top Social Posts

Top posts by engagements in the last [--] hours

"CRIPSR/Cas9 gene therapy has prevented vision loss from Fuchs' endothelial corneal dystrophy according to findings from a preclinical study published in eLife. https://buff.ly/3JilHpK https://buff.ly/3JilHpK"
X Link 2021-12-28T15:08Z [---] followers, [--] engagements

"The CRIPSR-edited neoantigen-specific T cell therapy NeoTCR-P1 demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC [----]. http://ow.ly/hFjg50LBzyy http://ow.ly/hFjg50LBzyy"
X Link 2022-11-12T15:05Z [---] followers, [--] engagements

"ICYMI: EPKINLYs (@abbvie) approval was based on data from the phase 1/2 EPCORE NHL-1 clinical trial (NCT03625037). Read more:"
X Link 2023-06-29T22:31Z [---] followers, [---] engagements

"The FDA has accepted @pfizer's BLA for fidanacogene elaparvovec AAV gene therapy for treating #hemophilia B with a PDUFA date set for Q2 2024"
X Link 2023-06-29T22:40Z [---] followers, [--] engagements

"Four weeks following the administration of @TayshaGTx's TSHA-102 the patient demonstrated a score of [--] (much improved) on a version of the Clinical Global ImpressionsImprovement scale adapted to #RettSyndrome. #genetherapy Read more:"
X Link 2023-08-14T16:49Z [---] followers, [--] engagements

"In terms of safety @TayshaGTx stated that TSHA-102 was well-tolerated in patients with #Rettsyndrome and that at [--] weeks after dosing no treatment-emergent serious adverse events had occurred"
X Link 2023-08-15T13:45Z [---] followers, [--] engagements

"CART-ddBCMA is @arcellxs lead product candidate and is being co-developed together with @KitePharma under a global strategic collaboration agreement. #mmsm #MultipleMyeloma #celltherapy Read more:"
X Link 2023-08-15T18:43Z [---] followers, [---] engagements

"ICYMI: Four weeks following administration of @TayshaGTx's TSHA-102 the patient showed a score of [--] (much improved) on a version of the Clinical Global ImpressionsImprovement scale adapted to #RettSyndrome. #genetherapy More:"
X Link 2023-08-16T15:47Z [---] followers, [--] engagements

"ICYMI: The @US_FDA has approved @bmsnewss luspatercept-aamt (Reblozyl) as a first-line treatment for #anemia in adult patients with very low to intermediate-risk #MyelodysplasticSyndromes who may require RBC transfusions. More:"
X Link 2023-08-29T21:30Z [---] followers, [--] engagements

"Garzone noted that dosing of the patients in the trials first cohort has been completed and that to date the treatment has been well-tolerated. #celltherapy #ovca #OvarianCancer #CARTCR @AnixaBio Watch:"
X Link 2023-09-07T15:29Z [---] followers, [--] engagements

"ICYMI: Garzone noted that dosing of the patients in the trials first cohort has been completed and that to date the treatment has been well-tolerated. #celltherapy #ovca #OvarianCancer #CARTCR @AnixaBio Watch:"
X Link 2023-09-09T03:20Z [---] followers, [--] engagements

"ICYMI: @biocardia_inc is considering replacing the 6MWT with a more objective outcome measurement. #HeartFailure #celltherapy Read more:"
X Link 2023-09-13T13:10Z [---] followers, [--] engagements

"ICYMI: @BeamTx's BEAM-201 is an anti-CD7 allogeneic CAR T-cell therapy and is the first quadruplex-edited allogeneic CAR T-cell therapy candidate to enter clinical-stage developmentl. #celltherapy #CAR-T #leukemia #lymphoma #lymsm #leusm More:"
X Link 2023-09-13T21:30Z [---] followers, [--] engagements

"Sattar Khoshkhoo MD the founding director of the Epilepsy Genetics Clinic @BrighamWomens discussed his nonclinical research on disease pathogenesis in MTL #epilepsy"
X Link 2023-09-14T13:35Z [---] followers, [--] engagements

"Unlocking the potential of #genetherapy for rare #GeneticDiseases requires a closer look at costs. #newbornscreening #ANA2023 Watch now:"
X Link 2023-09-14T15:07Z [---] followers, [--] engagements

"ICYMI: Unlocking the potential of #genetherapy for rare #GeneticDiseases requires a closer look at costs. #newbornscreening #ANA2023 Watch now:"
X Link 2023-09-16T01:55Z [---] followers, [--] engagements

".@KyvernaTs KYV-101 has been well-tolerated in the first patient with #lupus nephritis dosed in a clinical trial. Read more about it now"
X Link 2023-09-16T18:10Z [---] followers, [--] engagements

"HEMO-CAR-T is an autologous #CAR-T #celltherapy developed with the use of @HemogenyxPharmas proprietary humanised monoclonal antibody against an #AML target. #AcuteMyeloidLeukemia #leusm #leukemia Read more:"
X Link 2023-09-17T21:40Z [---] followers, [--] engagements

"ICYMI: @OmegaTXs lead MYC-targeted OEC candidate OTX-2002 is currently being evaluated in a phase 1/2 clinical trial (NCT05497453). #solidtumor #HepatocellularCarcinoma #solidtumors #livercancer #EpigeneticTherapy Watch now:"
X Link 2023-09-18T01:55Z [---] followers, [--] engagements

"ICYMI: "I think the main takeaway is that we need to rethink everything." Click the link below to read our full interview with @SattarKhoshkhoo at #AN2023 covering the potential of #targetedtherapy and #genetherapy in #MesialTemporalLobeEpilepsy:"
X Link 2023-09-19T02:50Z [---] followers, [--] engagements

".@RocketPharma has come into alignment with the FDA on plans for its pivotal phase [--] clinical trial evaluating RP-A501 gene therapy intended to treat #Danondisease"
X Link 2023-09-19T18:15Z [---] followers, [--] engagements

"ICYMI: Arsa-cel has had its Prescription Drug User Fee Act (#PDUFA) date set for March [--] [----]. #MetachromaticLeukodystrophy #celltherapy #BiologicLicenseApplication #Libmeldy Read more:"
X Link 2023-09-20T15:48Z [---] followers, [--] engagements

"Pat Furlong BSN RN founding president and chief executive officer of PPMD discussed recent and upcoming milestones in the field of #duchenne"
X Link 2023-09-21T13:35Z [---] followers, [---] engagements

"ICYMI: The data reported by Ocugen on September [--] [----] is an update on results previously reported in April of this year. #LeberCongenitalAmaurosis #RetinitisPigmentosa #genetherapy Read more:"
X Link 2023-09-22T13:10Z [---] followers, [----] engagements

"Shankar Musunuri PhD chairman chief executive officer and cofounder @Ocugen shared the potential advantages of using a gene-agnostic modifier #genetherapy as opposed to a traditional gene-replacement therapy. #retinitispigmentosa Watch now:"
X Link 2023-09-24T21:30Z [---] followers, [----] engagements

"ICYMI: MYCHELANGELO-1 is a 2-part study the first assessing OTX-2002 (@OmegaTX) as a monotherapy and the second assessing it as a combination therapy. #RNAtherapy #solidtumor #solidtumors #hepatocellularcarcinoma Read more:"
X Link 2023-10-02T23:45Z [---] followers, [--] engagements

"ICYMI: CGTLive spoke with @bvantine1 professor medicine and pediatrics @WUSTL during Julys #SarcomaAwarenessMonth to learn more about the future challenges and road ahead for the field of #celltherapy in #sarcoma. Watch now:"
X Link 2023-10-03T01:55Z [---] followers, [--] engagements

"@bluebirdbio Modifies Agreement With its Manufacturer @LonzaGroup @abbvie Bows Out of Collaboration With @CaribouBio Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix"
X Link 2023-10-04T19:57Z [---] followers, [--] engagements

"The new data were presented at the Annual Meeting of The European Association for the Study of Diabetes (#EASD2023) held October 2-6 in Hamburg Germany. #type1diabetes #diabetes #celltherapy #insulin @EASDnews @VertexPharma Read more:"
X Link 2023-10-04T23:45Z [---] followers, [---] engagements

"ICYMI: As of the August [--] [----] data cut-off all [--] patients who received GC012F in the trial had achieved an sCR with minimal residual disease negativity. $GRCL #MultipleMyeloma #mmsm Read more: https://www.cgtlive.com/view/gracell-bcma-cd19-car-t-gc012f-achieves-100-stringent-cr-rate-newly-diagnosed-multiple-myeloma https://www.cgtlive.com/view/gracell-bcma-cd19-car-t-gc012f-achieves-100-stringent-cr-rate-newly-diagnosed-multiple-myeloma"
X Link 2023-10-05T01:55Z [---] followers, [--] engagements

"ICYMI: The new data were presented at the Annual Meeting of The European Association for the Study of Diabetes (#EASD2023) held October 2-6 in Hamburg Germany. #type1diabetes #diabetes #celltherapy #insulin @EASDnews @VertexPharma Read more:"
X Link 2023-10-06T21:30Z [---] followers, [--] engagements

"AVB-001 which is administered intraperitoneally is based on @AvengeBios LOCOcyte platform and is intended to generate native hIL-2 on a continuous basis. #celltherapy #ovca #ovariancancer Read more:"
X Link 2023-10-10T15:50Z [---] followers, [--] engagements

"@AviadoBio noted that patients will receive the gene therapy via a 1-time administration to the thalamus by way of a minimally-invasive stereotactic neurosurgical procedure. #genetherapy #dementia #FrontotemporalDementia #intrathalamic Read more:"
X Link 2023-10-10T19:53Z [---] followers, [--] engagements

"ICYMI: @AviadoBio noted that patients will receive the gene therapy via a 1-time administration to the thalamus by way of a minimally-invasive stereotactic neurosurgical procedure. #genetherapy #dementia #FrontotemporalDementia #intrathalamic Read more:"
X Link 2023-10-11T22:38Z [---] followers, [--] engagements

"ICYMI: I think the biggest implications are that B-cells producing therapeutic proteins could be a new cell therapy that will bein the midterm anywaycoming to clinical trials. -@ScienceRicker (@seattlechildren) #ASGCT23 #PlasmaCells #leusm Watch:"
X Link 2023-10-13T18:36Z [---] followers, [--] engagements

"🩸 Lovo-cel's PDUFA date approaches on December [--] [----] marking a potential milestone in Sickle Cell Disease #SCD treatment. Explore the therapy's journey from clinical trials to its anticipated approval"
X Link 2023-10-21T20:05Z [---] followers, [--] engagements

"Dr. Milind Desai discusses TN-201 an investigational gene therapy for MYBPC3-associated Hypertrophic Cardiomyopathy. This promising therapy aims to correct genetic mutations in heart cells. #Cardiology"
X Link 2023-10-21T22:10Z [---] followers, [---] engagements

"TN-201 #genetherapy by Tenaya Therapeutics could fill the gap of precision therapies for Hypertrophic Cardiomyopathy by addressing the genetic basis of the disease. Learn more about it now"
X Link 2023-10-23T00:30Z [---] followers, [--] engagements

"Desai emphasized that #genetherapy is still very new territory in #cardiovascular medicine especially for #HypertrophicCardiomyopathy and therefore demonstrating safety in the clinical setting is of very high importance. @TenayaThera More:"
X Link 2023-10-23T11:05Z [---] followers, [--] engagements

"Anticipation grows as we approach the PDUFA date for lovo-cel in sickle cell treatment. While the therapy offers hope it's crucial to address access and disparities to ensure all #SCD patients benefit"
X Link 2023-10-24T00:45Z [---] followers, [--] engagements

"ICYMI: @MasriAhmadMD also summed up his thoughts on #WorldAmyloidosisDay and gave his main message regarding #amyloidosis for doctors and the broader healthcare community to keep in mind in [----]. #genetherapy #ATTR #ATTRAmyloidosis @intelliatx Watch:"
X Link 2023-10-27T13:10Z [---] followers, [---] engagements

"ICYMI: @BrettKope noted that the approval of @KrystalBiotech's B-VEC #genetherapy represents a major milestone for the #EpidermolysisBullosa treatment landscape. #EBAwarenessWeek2023 #EBAwarenessWeek Watch:"
X Link 2023-10-27T17:20Z [---] followers, [--] engagements

"@ultragenyx to Launch Cash Neutral Spinout Focused on #AlzheimerDisease (#Alzheimers) @BeamTx to Let Go of 20% of Employees Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix"
X Link 2023-10-27T23:35Z [---] followers, [--] engagements

"Dr. Julie Kanter shares insights from her experience as an investigator for Lovo-Cel clinical trials in #SickleCell. Watch it now"
X Link 2023-10-28T20:40Z [---] followers, [--] engagements

"On World Amyloidosis Day Dr. Ahmad Masri highlighted the significance of raising awareness about #amyloidosis and the potential of NTLA-2001"
X Link 2023-10-29T13:15Z [---] followers, [--] engagements

"FLT201 gene therapy has shown a favorable safety profile and prompted robust GCase expression in the plasma and normalized levels in cells of patients with #Gaucher disease type 1"
X Link 2023-10-29T15:35Z [---] followers, [--] engagements

"Gene and cell therapy advancements are shaping the future of healthcare. From long-term risks to promising trials this week's #WeeklyRewind sheds light on the field's progress"
X Link 2023-10-29T18:01Z [---] followers, [--] engagements

"Shifting from bone marrow to plexifor-mobilized stem cells: A key lesson in the development of Lovo-Cel gene therapy for #SickleCell Disease. Listen to more from Dr. Julie Kanter now"
X Link 2023-10-29T22:50Z [---] followers, [--] engagements

"Maria Pia Morelli MD PhD assistant professor at MD Anderson Cancer Center discussed factors to consider when trying to treat patients with gastrointestinal cancers with cell therapy. Watch it now"
X Link 2023-10-30T15:14Z [---] followers, [--] engagements

"In [----] the approach to managing ATTR #Amyloidosis looks remarkably different from a decade ago. Dr. Ahmad Masri shares insights on the changing landscape"
X Link 2023-10-30T15:25Z [---] followers, [--] engagements

"The first child with OTOF-related hearing loss treated with gene therapy DB-OTO in the phase 1/2 CHORD clinical trial (NCT05788536) has shown some improvement in auditory responses"
X Link 2023-10-30T19:05Z [---] followers, [--] engagements

"Our #WeeklyRewind highlights innovations driving the gene and cell therapy field forward each week. Stay tuned for more updates"
X Link 2023-10-30T20:05Z [---] followers, [--] engagements

"Caribou Biosciences brings a new approach to #AML treatment with CB-012 with a clinical trial coming soon"
X Link 2023-10-30T22:30Z [---] followers, [--] engagements

"Will Lovo-Cel make history as the first gene therapy approved for #SickleCell Disease Check out Dr. Julie Kanter's insights into the therapy now"
X Link 2023-10-31T01:05Z [---] followers, [--] engagements

"Watch Maria Pia Morelli MD PhD assistant professor at MD Anderson Cancer Center discuss the EVEREST-1 clinical trial of A2B530 now"
X Link 2023-10-31T16:16Z [---] followers, [--] engagements

"ICYMI: Watch Maria Pia Morelli MD PhD assistant professor at MD Anderson Cancer Center discuss the EVEREST-1 clinical trial of A2B530:"
X Link 2023-11-01T15:55Z [---] followers, [--] engagements

"Atamyo's ATA-100 #genetherapy for LGMD2I/R9 receives clearance for the second cohort"
X Link 2023-11-06T01:40Z [---] followers, [--] engagements

"BRL-201 CRISPR-/Cas9-based CAR T-cell therapy yielded a 100% ORR in [--] patients with relapsed/refractory (r/r) non-Hodgkins lymphoma treated in a phase 1/2 clinical trial in China. #SITC23 #lymsm"
X Link 2023-11-08T16:20Z [---] followers, [--] engagements

"ICYMI: BRL-201 CRISPR-/Cas9-based CAR T-cell therapy yielded a 100% ORR in [--] patients with relapsed/refractory (r/r) non-Hodgkins lymphoma treated in a phase 1/2 clinical trial in China. #SITC23 #lymsm"
X Link 2023-11-09T14:10Z [---] followers, [--] engagements

"The @US_FDA has approved Takeda Pharmaceuticals Adzynma (TAK-755) as a prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)"
X Link 2023-11-09T21:51Z [---] followers, [--] engagements

"ICYMI: The @US_FDA has approved Takeda Pharmaceuticals Adzynma (TAK-755) as a prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)"
X Link 2023-11-11T02:55Z [---] followers, [--] engagements

"@OSUGeneTherapy Enlists CDMO @AndelynBio Ajinomoto Co. Inc. To Bring @ForgeBio Into the Fold Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://ow.ly/VHqr50Q87AL https://ow.ly/VHqr50Q87AL"
X Link 2023-11-15T23:05Z [---] followers, [--] engagements

"ICYMI: @OSUGeneTherapy Enlists CDMO @AndelynBio Ajinomoto Co. Inc. To Bring @ForgeBio Into the Fold Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://ow.ly/VHqr50Q87AL https://ow.ly/VHqr50Q87AL"
X Link 2023-11-17T00:45Z [---] followers, [--] engagements

"At [--] weeks after receiving their final dose 44% to 89% of [--] evaluable patients either showed improvement or maintained stability on all cognitive scores in comparison to their results at [--] week after the final dose. #Alzheimers @NKGenBiotech More: https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-improves-cognitive-function-alzheimer-disease-up-11-weeks https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-improves-cognitive-function-alzheimer-disease-up-11-weeks"
X Link 2023-11-22T12:05Z [---] followers, [--] engagements

"ICYMI: At [--] weeks after their final dose 44% to 89% of [--] evaluable patients either showed improvement or maintained stability on all cognitive scores in comparison to their results at [--] week after the final dose. #Alzheimers @NKGenBiotech More: https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-improves-cognitive-function-alzheimer-disease-up-11-weeks https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-improves-cognitive-function-alzheimer-disease-up-11-weeks"
X Link 2023-11-23T20:15Z [---] followers, [--] engagements

"50% of the patients who had a stable ADCOMS score at [--] week after the final dose remained stable at [--] weeks after the final dose. #Alzheimers #celltherapy #NaturalKiller #NKcell #AlzheimersDisease @NKGenBiotech More: https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-improves-cognitive-function-alzheimer-disease-up-11-weeks https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-improves-cognitive-function-alzheimer-disease-up-11-weeks"
X Link 2023-11-24T16:15Z [---] followers, [--] engagements

"A2 Biotherapeutics is testing A2B530 a #CAR-T cell therapy addressing current safety concerns in solid tumors. The phase [--] EVEREST-1 trial evaluates its potential in colorectal and pancreatic cancers"
X Link 2023-11-25T14:15Z [---] followers, [---] engagements

"New modifications in CardiAMP #HeartFailure trial with changes in eligibility endpoints and logistics. Stay tuned for the latest updates on this innovative trial. @biocardia"
X Link 2023-11-26T23:35Z [---] followers, [--] engagements

"Logic-gating in A2B530 #CAR-T cell therapy shows promise in expanding target options. Dr. Morelli reveals plans for EVEREST-2 targeting mesothelin highlighting the technology's potential in treating various cancers"
X Link 2023-11-27T18:30Z [---] followers, [--] engagements

"Kicking off our coverage of the Cell Therapy for Autoimmune Disease Summit Stay tuned #celltherapy #AutoimmuneDisease"
X Link 2023-11-29T22:21Z [---] followers, [--] engagements

".@CARsgen_Ther said in its notice of the clinical hold to the Hong Kong Stock Exchange that it plans to conduct a comprehensive review. #celltherapy #CART #leukemia #solidtumors Read more:"
X Link 2023-12-19T22:20Z [---] followers, [--] engagements

"University College London has initiated the single site trial at Great Ormond Street Hospital London. #GeneTherapy #RareDisease @UCL"
X Link 2024-01-11T20:23Z [---] followers, [--] engagements

"ICYMI: University College London has initiated the single site trial at Great Ormond Street Hospital London. #GeneTherapy #RareDisease @UCL"
X Link 2024-01-13T00:45Z [---] followers, [--] engagements

".@barrybyrne1 spoke about the ability of directed evolution to identify myotropic AAV vectors and how these efforts may form the basis of the next frontier in AAV vector-based gene therapy #genetherapy #MDAconference #MDA #MDA2024 #AAV @MDAorg More:"
X Link 2024-01-29T12:05Z [---] followers, [--] engagements

"@AstellasUS and @MassGenBrigham Join Forces @GamidaCellTx Looking to Sell Off Assets or Merge Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix"
X Link 2024-01-31T21:08Z [---] followers, [--] engagements

"ICYMI: @barrybyrne1 spoke about the ability of directed evolution to identify myotropic AAV vectors and how these efforts may form the basis of the next frontier in AAV vector-based #genetherapy #MDAconference #MDA #MDA2024 #AAV @MDAorg More:"
X Link 2024-02-02T00:45Z [---] followers, [---] engagements

"ICYMI: @AstellasUS and @MassGenBrigham Join Forces @GamidaCellTx Looking to Sell Off Assets or Merge Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix"
X Link 2024-02-02T02:55Z [---] followers, [--] engagements

"In terms of safety no serious adverse events deemed related to arsa-cel were reported. #Leukodystrophy #WORLDSympsosium @Orchard_Tx Read more:"
X Link 2024-02-08T12:05Z [---] followers, [--] engagements

"Thomas McCauley PhD chief scientific officer at @OmegaTx discussed how the MYCHELANGEO-1 trial may validate the companys OEC platform. Watch it now. #Epigenomics #HepatocellularCarcinoma"
X Link 2024-02-08T17:29Z [---] followers, [--] engagements

"In the peripheral blood mononuclear cells (PBMCs) and in CD15+ cells ARSA activity reached supranormal levels. #Leukodystrophy #WORLDSympsosium #LateJuvenile @Orchard_Tx More:"
X Link 2024-02-09T12:05Z [---] followers, [--] engagements

"ICYMI: In terms of safety no serious adverse events deemed related to arsa-cel were reported. #Leukodystrophy #WORLDSympsosium @Orchard_Tx Read more:"
X Link 2024-02-09T14:10Z [---] followers, [--] engagements

""Artificial intelligence offers a tool to tackle problems we were previously not able to solve or would need to be solved with in multicenter international collaborations to gain the power needed." - David Shyr MD @StanfordMed at #ASH23"
X Link 2024-02-11T02:36Z [---] followers, [--] engagements

"The gene-edited cell therapy also showed a safety profile consistent with that previously seen in patients with early-onset MLD. #WORLDSymposium"
X Link 2024-02-11T18:50Z [---] followers, [--] engagements

"Orchard Therapeutics arsa-cel approved as Libmeldy in Europe a gene-edited cell therapy intended to treat MLD has enabled restoration of ARSA enzyme activity among patients with the late juvenile (LJ) form of MLD. #WORLDSymposium"
X Link 2024-02-12T17:01Z [---] followers, [--] engagements

"ICYMI: At the 24-week analysis patients who received the high dose achieved an 89% decrease in annualized antiVEGF injection rates. #wetAMD @4DMTx More:"
X Link 2024-02-14T02:55Z [---] followers, [--] engagements

"Tivanisiran is a small interfering RNA (siRNA) that inhibits the synthesis of Transient Receptor Potential Vanilloid-1 (TRPV1). #SjgrensSyndrome #DryEye #RNAtherapy #RNA #Sylentis Read more:"
X Link 2024-02-15T02:55Z [---] followers, [--] engagements

"ICYMI: Tivanisiran is a small interfering RNA (siRNA) that inhibits the synthesis of Transient Receptor Potential Vanilloid-1 (TRPV1). #SjgrensSyndrome #DryEye #RNAtherapy #RNA #Sylentis Read more:"
X Link 2024-02-16T00:45Z [---] followers, [--] engagements

"By clearing out that toxic accumulation of heparin sulfate over the long term we're starting to see a benefit in the overall cognition of children." - Heather Lau MD @Ultragenyx #MPS"
X Link 2024-02-18T16:20Z [---] followers, [--] engagements

".@VerveTx plans to expand evaluations into the US after an IND clearance was delayed by a clinical hold. #Cardiology #Hypercholesteremia #CRISPR"
X Link 2024-02-19T23:21Z [---] followers, [--] engagements

"@Ginkgo Snags Multiple Acquisitions #KenaiTherapeutics Garners $82 Million in Series A Round of Financing Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix"
X Link 2024-03-07T00:35Z [---] followers, [--] engagements

"Patients in Cohort [--] will no longer be dosed in a staggered manner as in the original protocol but may now instead be dosed in parallel. #RettSyndrome #genetherapy @NeurogeneInc Read more:"
X Link 2024-03-07T19:24Z [---] followers, [--] engagements

"ICYMI: @Ginkgo Snags Multiple Acquisitions #KenaiTherapeutics Garners $82 Million in Series A Round of Financing Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix"
X Link 2024-03-07T22:30Z [---] followers, [--] engagements

"ICYMI: Patients in Cohort [--] will no longer be dosed in a staggered manner as in the original protocol but may now instead be dosed in parallel. #RettSyndrome #genetherapy @NeurogeneInc Read more:"
X Link 2024-03-08T18:20Z [---] followers, [--] engagements

"FDA's #ODAC meeting votes unanimously in favor of cilta-cel's benefit-risk profile. @JanssenUS @LegendBiotech"
X Link 2024-03-15T16:51Z [---] followers, [---] engagements

"#BREAKING: #ODAC meeting also votes in favor of ide-cel's benefit-risk profile with [--] yes [--] no and [--] abstain votes"
X Link 2024-03-15T21:03Z [---] followers, [---] engagements

".@DLBHATTMD director of @MountSinaiHeart shared his optimism on data seen so far with VERVE-101. Watch now:"
X Link 2024-03-25T11:18Z [---] followers, [----] engagements

"ICYMI: @DLBHATTMD director of @MountSinaiHeart shared his optimism on data seen so far with VERVE-101. Watch now: https://www.cgtlive.com/view/deepak-bhatt-encouraging-data-gene-editing-hypercholesteremia https://www.cgtlive.com/view/deepak-bhatt-encouraging-data-gene-editing-hypercholesteremia"
X Link 2024-03-26T14:35Z [---] followers, [----] engagements

"@fiocruz_en and @caring_cross Join Forces to Increase Accessibility of CAR-T in #Brazil #Capstan Garners $175 Million in Series B Financing Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-march-27-2024 https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-march-27-2024"
X Link 2024-03-27T19:54Z [---] followers, [--] engagements

"ICYMI: @fiocruz_en and @caring_cross Join Forces to Increase Accessibility of CAR-T in #Brazil #Capstan Garners $175 Million in Series B Financing Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-march-27-2024 https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-march-27-2024"
X Link 2024-03-29T01:55Z [---] followers, [--] engagements

"ICYMI: This past Friday the FDA expanded ide-cel and cilta-cel CAR T-cell therapy indications to include earlier lines of treatment for #MultipleMyeloma. Keep up-to-date with breaking news at http://cgtlive.com http://cgtlive.com"
X Link 2024-04-07T20:20Z [---] followers, [---] engagements

".@NKGenBiotechs planned trial will seek to enroll up to [--] patients [--] of whom will be treated with SNK01 and [--] of whom will receive a placebo. #ParkinsonsAwarenessMonth #ParkinsonsDisease Read more: https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-cleared-us-clinical-trial-parkinson-disease https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-cleared-us-clinical-trial-parkinson-disease"
X Link 2024-04-30T19:16Z [---] followers, [--] engagements

"@Regeneron and @mammothbiosci Team Up for CRISPR-Focused Endeavor @Mustang_Bio Makes Public Offering Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-may-1-2024 https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-may-1-2024"
X Link 2024-05-01T19:44Z [---] followers, [--] engagements

"ICYMI: @NKGenBiotechs planned trial will seek to enroll up to [--] patients [--] of whom will be treated with SNK01 and [--] of whom will receive a placebo. #ParkinsonsAwarenessMonth #ParkinsonsDisease Read more: https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-cleared-us-clinical-trial-parkinson-disease https://www.cgtlive.com/view/nkgen-nk-cell-therapy-snk01-cleared-us-clinical-trial-parkinson-disease"
X Link 2024-05-01T23:45Z [---] followers, [--] engagements

"ICYMI: @Regeneron and @mammothbiosci Team Up for CRISPR-Focused Endeavor @Mustang_Bio Makes Public Offering Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-may-1-2024 https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-may-1-2024"
X Link 2024-05-02T13:10Z [---] followers, [--] engagements

"PJ Brooks PhD deputy director Division of Rare Diseases Research Innovation NCATS NIH discussed ongoing initiatives to facilitate rare disease drug development. https://www.cgtlive.com/view/nih-strategizes-to-streamline-gene-therapy-development https://www.cgtlive.com/view/nih-strategizes-to-streamline-gene-therapy-development"
X Link 2024-05-04T22:18Z [---] followers, [--] engagements

"ICYMI: Yesterday it was announced that a patient with #DMD has died in Pfizer's phase [--] trial of fordadistrogene movaparvovec. Read more: https://www.cgtlive.com/view/patient-dmd-dies-pfizer-phase-2-gene-therapy-trial https://www.cgtlive.com/view/patient-dmd-dies-pfizer-phase-2-gene-therapy-trial https://www.cgtlive.com/view/patient-dmd-dies-pfizer-phase-2-gene-therapy-trial https://www.cgtlive.com/view/patient-dmd-dies-pfizer-phase-2-gene-therapy-trial"
X Link 2024-05-09T01:55Z [---] followers, [--] engagements

"It is hard to understand the gravity of these medicines because we always focus on such positive outcomes. But there's a dark side to it. And it's scary." - Leigh Ramos-Platt MD @KeckMedicineUSC #ASGCT24. Watch now: https://www.cgtlive.com/view/ramos-platt-allowing-access-ensuring-preparation-gene-therapies https://www.cgtlive.com/view/ramos-platt-allowing-access-ensuring-preparation-gene-therapies"
X Link 2024-05-27T13:19Z [---] followers, [---] engagements

"BREAKING: The @US_FDA has approved @bmsnews's lisocabtagene maraleucel a CAR T-cell therapy for treating adults with r/r mantle cell #lymphoma who have been previously treated with [--] lines of systemic therapy including a BTK inhibitor. #lisocel https://www.cgtlive.com/view/liso-cel-breyanzi-approved-relapsed-refractory-mantle-cell-lymphoma https://www.cgtlive.com/view/liso-cel-breyanzi-approved-relapsed-refractory-mantle-cell-lymphoma"
X Link 2024-05-30T17:05Z [---] followers, [--] engagements

"ICYMI: Earlier today the @US_FDA approved @bmsnews's liso-cel a CAR T-cell therapy for treating adults with r/r mantle cell #lymphoma who have been previously treated with [--] lines of systemic therapy including a BTK inhibitor. #lisocel More: https://www.cgtlive.com/view/liso-cel-breyanzi-approved-relapsed-refractory-mantle-cell-lymphoma https://www.cgtlive.com/view/liso-cel-breyanzi-approved-relapsed-refractory-mantle-cell-lymphoma"
X Link 2024-05-31T01:55Z [---] followers, [---] engagements

"ICYMI: Yesterday the @US_FDA approved @bmsnews's liso-cel a CAR T-cell therapy for treating adults with r/r mantle cell #lymphoma who have been previously treated with [--] lines of systemic therapy including a BTK inhibitor. #lisocel More: https://www.cgtlive.com/view/liso-cel-breyanzi-approved-relapsed-refractory-mantle-cell-lymphoma https://www.cgtlive.com/view/liso-cel-breyanzi-approved-relapsed-refractory-mantle-cell-lymphoma"
X Link 2024-05-31T23:45Z [---] followers, [--] engagements

"CIFFREO did not demonstrate improvement in gross motor function on the NSAA for patients treated with the #genetherapy in comparison to patients treated with placebo at [--] year posttreatment. @pfizer #DuchenneMuscularDystrophy More: https://www.cgtlive.com/view/pfizer-phase-3-trial-dmd-gene-therapy-fordadistrogene-movaparvovec-misses-mark-primary-end-point https://www.cgtlive.com/view/pfizer-phase-3-trial-dmd-gene-therapy-fordadistrogene-movaparvovec-misses-mark-primary-end-point"
X Link 2024-06-13T15:43Z [---] followers, [---] engagements

"In all of these cases we saw reduction of the level of expression of the proteins in the serum." -Steve Kanner PhD #ASGCT2024 #CRISPR @CaribouBio More: https://www.cgtlive.com/view/caribou-biosciences-chrdna-technology-enable-new-treatments-attr-familial-hypercholesterolemia https://www.cgtlive.com/view/caribou-biosciences-chrdna-technology-enable-new-treatments-attr-familial-hypercholesterolemia"
X Link 2024-07-29T11:05Z [---] followers, [--] engagements

"ICYMI: In all of these cases we saw reduction of the level of expression of the proteins in the serum." -Steve Kanner PhD #ASGCT2024 #CRISPR @CaribouBio More: https://www.cgtlive.com/view/caribou-biosciences-chrdna-technology-enable-new-treatments-attr-familial-hypercholesterolemia https://www.cgtlive.com/view/caribou-biosciences-chrdna-technology-enable-new-treatments-attr-familial-hypercholesterolemia"
X Link 2024-07-30T13:10Z [---] followers, [--] engagements

"In light of the disappointing results Pfizer does not have plans to continue development of fordadistrogene movaparvovec a @pfizer spokesperson said in a statement issued to CGTLive. #genetherapy #Duchenne #MuscularDystrophy Read more: https://www.cgtlive.com/view/pfizer-development-dmd-gene-therapy-fordadistrogene-movaparvovec https://www.cgtlive.com/view/pfizer-development-dmd-gene-therapy-fordadistrogene-movaparvovec"
X Link 2024-07-30T22:05Z [---] followers, [--] engagements

"ICYMI: In light of the disappointing results Pfizer does not have plans to continue development of fordadistrogene movaparvovec a @pfizer spokesperson said in a statement issued to CGTLive. #genetherapy #Duchenne #MuscularDystrophy Read more: https://www.cgtlive.com/view/pfizer-development-dmd-gene-therapy-fordadistrogene-movaparvovec https://www.cgtlive.com/view/pfizer-development-dmd-gene-therapy-fordadistrogene-movaparvovec"
X Link 2024-08-01T01:58Z [---] followers, [--] engagements

"NGN-401 is an investigational adeno-associated virus (AAV9) gene therapy that delivers the full-length human MECP2 gene using @NeurogeneIncs EXACT technology. #RettSyndrome #genetherapy Read more: https://www.cgtlive.com/view/rett-syndrome-gene-therapy-rmat-designation https://www.cgtlive.com/view/rett-syndrome-gene-therapy-rmat-designation"
X Link 2024-08-09T17:20Z [---] followers, [--] engagements

"@genprex Garners Patent for Reqorsa Combination Treatment in #Singapore @SangamoTx and @genentech Team Up to Tackle #NeurodegenerativeDisease Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-august-14-2024 https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-august-14-2024"
X Link 2024-08-14T19:42Z [---] followers, [--] engagements

"ICYMI: The technology has really matured to a point where we can take that next leap as a field to bring gene therapies into a broader universe of diseases." -Shankar Ramaswamy MD #genetherapy #ASGCT2024 @kriyatx Read more: https://www.cgtlive.com/view/bringing-gene-therapy-common-diseases https://www.cgtlive.com/view/bringing-gene-therapy-common-diseases"
X Link 2024-08-15T01:55Z [---] followers, [--] engagements

"According to @CartesianTX Descartes-15 includes technology intended to provide it with predictable and controllable pharmacokinetics and enhanced CAR stability. #mmsm #MultipleMyeloma #celltherapy Read more: https://www.cgtlive.com/view/cartesian-therapeutics-doses-first-patient-mrna-car-t-descartes-15-trial-multiple-myeloma https://www.cgtlive.com/view/cartesian-therapeutics-doses-first-patient-mrna-car-t-descartes-15-trial-multiple-myeloma"
X Link 2024-09-06T11:05Z [---] followers, [--] engagements

"Belief BioMed and @ask_bio Team Up @OriBiotech and @CRiverLabs Announce Results from Test of Next-Generation Manufacturing Platform Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-september-25-2024 https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-september-25-2024"
X Link 2024-09-25T20:17Z [---] followers, [--] engagements

"As I mentioned if you look at the phase 1/2 efficacy outcome close to 60% of intent to treat patients derived from our phase 1/2 study responded on our primary end point which we are using in the phase [--] study. #genetherapy #Ocugen @Ocugen Watch: https://www.cgtlive.com/view/ird-gene-therapy-ocu400-phase-1-2-trial https://www.cgtlive.com/view/ird-gene-therapy-ocu400-phase-1-2-trial"
X Link 2024-10-09T14:07Z [---] followers, [---] engagements

"ICYMI: .if you look at the phase 1/2 efficacy outcome close to 60% of intent to treat patients derived from our phase 1/2 study responded on our primary end point which we are using in the phase [--] study. #genetherapy #Ocugen @Ocugen Watch: https://www.cgtlive.com/view/ird-gene-therapy-ocu400-phase-1-2-trial https://www.cgtlive.com/view/ird-gene-therapy-ocu400-phase-1-2-trial"
X Link 2024-10-11T14:40Z [---] followers, [----] engagements

"ICYMI: "In summary we definitely exceeded our expectations with the outcomes of the small study." #Alzheimers #AlzheimersDisease #celltherapy @LGVNSocial More: https://www.cgtlive.com/view/promising-data-lomecel-b-alzheimer-diseaseutm_source=twitter&utm_medium=social&utm_campaign=30bded19-74da-4d8e-95f2-1501e375afb1 https://www.cgtlive.com/view/promising-data-lomecel-b-alzheimer-diseaseutm_source=twitter&utm_medium=social&utm_campaign=30bded19-74da-4d8e-95f2-1501e375afb1"
X Link 2024-10-23T21:30Z [---] followers, [--] engagements

"Notably no serious adverse events occurred among the patients treated in the phase [--] portion. #genetherapy #Ophthalmology #ocugen @Ocugen More: https://www.cgtlive.com/view/ocugen-green-light-phase-2-portion-trial-evaluating-stargardt-gene-therapy-ocu410stutm_source=twitter&utm_medium=social&utm_campaign=14216f27-00a3-4845-afe5-91d5be747cc7 https://www.cgtlive.com/view/ocugen-green-light-phase-2-portion-trial-evaluating-stargardt-gene-therapy-ocu410stutm_source=twitter&utm_medium=social&utm_campaign=14216f27-00a3-4845-afe5-91d5be747cc7"
X Link 2024-10-24T21:50Z [---] followers, [----] engagements

"ICYMI: @ocuphire and @OpusGenetics Merge AvenCell Rakes in $112 Million for Switchable CAR-T Tech Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-october-23-2024utm_source=twitter&utm_medium=social&utm_campaign=81b28064-00a5-4336-b0f8-41553cb6746d https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-october-23-2024utm_source=twitter&utm_medium=social&utm_campaign=81b28064-00a5-4336-b0f8-41553cb6746d"
X Link 2024-10-24T23:50Z [---] followers, [--] engagements

"ICYMI: Among [--] patients treated in STAAR who had greater than [--] year of follow-up a positive annualized eGFR slope emerged from improvements in the mean and median eGFR levels that were recorded. #Fabry #FabryDisease #genetherapy @SangamoTx More: https://www.cgtlive.com/view/sangamo-reaches-accord-fda-plans-accelerated-approval-pathway-fabry-disease-gene-therapy-st-920utm_source=twitter&utm_medium=social&utm_campaign=38d06b58-543c-4061-8eb5-6d6c8c2a69ca"
X Link 2024-10-26T01:45Z [---] followers, [--] engagements

"#BREAKING: The @US_FDA has approved obe-cel (Aucatzyl; Autolus Inc) a genetically modified T-cell immunotherapy for the treatment of adults with r/r B-cell precursor acute lymphoblastic #leukemia. #celltherapy #leusm $AUTL Read more: https://www.cgtlive.com/view/fda-approves-obe-cel-adults-relapsed-refractory-b-cell-precursor-acute-lymphoblastic-leukemia https://www.cgtlive.com/view/fda-approves-obe-cel-adults-relapsed-refractory-b-cell-precursor-acute-lymphoblastic-leukemia"
X Link 2024-11-08T22:26Z [---] followers, [---] engagements

"ICYMI: Yesterday @PTCBios eladocagene exuparvovec (marketed as #Kebilidi) an AAV2-based #genetherapy was approved by the @US_FDA for the treatment of children and adults with of aromatic L-amino acid decarboxylase (#AADC) deficiency. More: https://www.cgtlive.com/view/fda-approves-ptc-therapeutics-gene-therapy-upstaza-aadc-deficiency https://www.cgtlive.com/view/fda-approves-ptc-therapeutics-gene-therapy-upstaza-aadc-deficiency"
X Link 2024-11-15T00:30Z [---] followers, [--] engagements

"The FDAs IND clearance allows for the geographic expansion of the phase 1b trial which has previously been cleared in Italy and France to the United States. #MuscularDystrophy #genetherapy #LimbGirdleMuscularDystrophy @AtamyoTX Read more: https://www.cgtlive.com/view/atamyo-therapeutics-gene-therapy-ata-200-cleared-trial-lgmd-type-2c-r5 https://www.cgtlive.com/view/atamyo-therapeutics-gene-therapy-ata-200-cleared-trial-lgmd-type-2c-r5"
X Link 2024-11-19T22:40Z [---] followers, [---] engagements

"ICYMI: The FDAs IND clearance allows for the geographic expansion of the phase 1b trial which has previously been cleared in Italy and France to the United States. #MuscularDystrophy #genetherapy #LimbGirdleMuscularDystrophy @AtamyoTX Read more: https://www.cgtlive.com/view/atamyo-therapeutics-gene-therapy-ata-200-cleared-trial-lgmd-type-2c-r5 https://www.cgtlive.com/view/atamyo-therapeutics-gene-therapy-ata-200-cleared-trial-lgmd-type-2c-r5"
X Link 2024-11-20T23:08Z [---] followers, [--] engagements

"In honor of #AlzheimersDiseaseAwarenessMonth observed annually in November CGTLive took a look back at some of the progress that has been made for cell therapy and gene therapy candidates in #Alzheimers over the past year. #AlzheimersDisease More: https://www.cgtlive.com/view/alzheimer-disease-awareness-month-2024-looking-back-year-progress-cell-gene-therapy https://www.cgtlive.com/view/alzheimer-disease-awareness-month-2024-looking-back-year-progress-cell-gene-therapy"
X Link 2024-11-26T22:45Z [---] followers, [---] engagements

"The single-arm GNT-018-IDES study will seek to enroll [--] adults with preformed antiAAV8 antibodies and #CriglerNajjar syndrome who need at least [--] hours per day of phototherapy. #genetherapy #CriglerNajjarSyndrome @GenethonFr @HansaBiopharma Read more: https://www.cgtlive.com/view/genethon-hansa-biopharma-launch-trial-gene-therapy-antibody-cleaving-enzyme-therapy-combination-treatment-crigler-najjar-syndrome https://www.cgtlive.com/view/genethon-hansa-biopharma-launch-trial-gene-therapy-antibody-cleaving-enzyme-therapy-combination-treatment-crigler-najjar-syndrome"
X Link 2024-12-04T00:30Z [---] followers, [---] engagements

"From tackling #AutoimmuneDiseases and #fibrosis to offering new hope for conditions such as #Alzheimers and #Parkinsons #NKcells are proving to be more versatileand more promisingthan ever before. Read more: https://www.cgtlive.com/view/power-potential-natural-killer-cell-therapies-new-awakening https://www.cgtlive.com/view/power-potential-natural-killer-cell-therapies-new-awakening"
X Link 2024-12-19T20:01Z [---] followers, [--] engagements

"According to @Capricors press release announcing the news the BLA is supported by data from the HOPE-2 clinical trial (NCT03406780) and HOPE-2s open-label extension (OLE) study (HOPE-2-OLE; NCT04428476). #Duchenne #MuscularDystrophy #DMD Read more: https://www.cgtlive.com/view/capricor-puts-rolling-bla-dmd-cardiomyopathy-cell-therapy-deramiocel-front-fda https://www.cgtlive.com/view/capricor-puts-rolling-bla-dmd-cardiomyopathy-cell-therapy-deramiocel-front-fda"
X Link 2025-01-02T17:36Z [---] followers, [--] engagements

"OCU400 is an adeno-associated virus #genetherapy delivering a nuclear hormone receptor gene called NR2E3. #Ocugen #RetinitisPigmentosa #Ophthalmology @Ocugen Read more: https://www.cgtlive.com/view/ocugen-retinitis-pigmentosa-gene-therapy-ocu400-sustains-improves-visual-function-2-year-follow-up-data https://www.cgtlive.com/view/ocugen-retinitis-pigmentosa-gene-therapy-ocu400-sustains-improves-visual-function-2-year-follow-up-data"
X Link 2025-01-13T21:55Z [---] followers, [---] engagements

"ICYMI: OCU400 is an adeno-associated virus #genetherapy delivering a nuclear hormone receptor gene called NR2E3. #Ocugen #RetinitisPigmentosa #Ophthalmology @Ocugen Read more: https://www.cgtlive.com/view/ocugen-retinitis-pigmentosa-gene-therapy-ocu400-sustains-improves-visual-function-2-year-follow-up-data https://www.cgtlive.com/view/ocugen-retinitis-pigmentosa-gene-therapy-ocu400-sustains-improves-visual-function-2-year-follow-up-data"
X Link 2025-01-15T22:25Z [---] followers, [---] engagements

"ICYMI: VG90 is intended to deliver a copy of CNGA1 to retinal photoreceptor cells via a proprietary AAV capsid referred to as vgAAV. #genetherapy #RetinitisPigmentosa #Ophthalmology Read more: https://www.cgtlive.com/view/vigeneron-snags-fda-rare-pediatric-disease-designation-cnga1-associated-retinitis-pigmentosa-gene-therapy https://www.cgtlive.com/view/vigeneron-snags-fda-rare-pediatric-disease-designation-cnga1-associated-retinitis-pigmentosa-gene-therapy"
X Link 2025-01-16T19:40Z [---] followers, [--] engagements

"ICYMI: "I think someone being transplant-ineligible is not equivalent to CAR-T ineligible." -Manali Kamdar MD PhD (@mana1981) #CART #lymsm #lymphoma More: https://www.cgtlive.com/view/transplant-eligibility-versus-car-t-eligibility https://www.cgtlive.com/view/transplant-eligibility-versus-car-t-eligibility"
X Link 2025-01-17T23:45Z [---] followers, [--] engagements

"ICYMI: @GalapagosGlobal and @CatalentPharma Join Forces @MeiraGTx Snags RPDD for #LeberCongenitalAmaurosis Gene Therapy Have a #celltherapy or #genetherapy update youd like to share Tag us with #AroundTheHelix https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-january-22-2025 https://www.cgtlive.com/view/around-the-helix-cell-and-gene-therapy-company-updates-january-22-2025"
X Link 2025-01-24T00:25Z [---] followers, [--] engagements

"In light of the IND clearance United Therapeutics intends to go forward with plans for a phase 1/2/3 clinical trial with the intention of supporting a BLA for the product. #KidneyTransplant #GeneEditing #xenotransplant Read more: https://www.cgtlive.com/view/united-therapeutics-gene-edited-kidney-xenotranspant-ukidney-cleared-trial https://www.cgtlive.com/view/united-therapeutics-gene-edited-kidney-xenotranspant-ukidney-cleared-trial"
X Link 2025-02-03T22:26Z [---] followers, [--] engagements

"Three patients treated with DT-DEC01 showed improvements in various functional tests including echocardiography arm movements grip strength and spirometry after 12-24 months of treatment #celltherapy #MDAconference #MuscularDystrophy @MDAorg More: https://hubs.li/Q03cnVgj0 https://hubs.li/Q03cnVgj0"
X Link 2025-03-18T20:46Z [---] followers, [--] engagements

"OAV101 IT is differentiated from the FDA-approved version of Zolgensma which is delivered systemically in that it is delivered directly to the spine. #MDAconference #SpinalMuscularAtrophy #genetherapy @Novartis @MDAorg Read more: https://hubs.li/Q03cC-hC0 https://hubs.li/Q03cC-hC0"
X Link 2025-03-19T21:35Z [---] followers, [--] engagements

"With regard to safety RGX-202 was characterized as well-tolerated" as of the February [--] [----] data cutoff. #MDAconference #genetherapy #Duchenne @REGENXBIO @MDAorg Read more: https://hubs.li/Q03cMfD80 https://hubs.li/Q03cMfD80"
X Link 2025-03-20T17:13Z [---] followers, [---] engagements

"OAV101 IT is differentiated from the FDA-approved version of Zolgensma which is delivered systemically in that it is delivered directly to the spine. #MDAconference #SpinalMuscularAtrophy #genetherapy @Novartis @MDAorg Read more: https://hubs.li/Q03cRdll0 https://hubs.li/Q03cRdll0"
X Link 2025-03-21T00:30Z [---] followers, [---] engagements

"Three patients treated with DT-DEC01 showed improvements in various functional tests including echocardiography arm movements grip strength and spirometry after 12-24 months of treatment #celltherapy #MDAconference #MuscularDystrophy @MDAorg More: https://hubs.li/Q03cYkmM0 https://hubs.li/Q03cYkmM0"
X Link 2025-03-21T19:30Z [---] followers, [---] engagements

"ICYMI: It's really moving medicine to be more like surgery in a waymore like a type of procedural healthcare where you're doing one-time interventions that have durable long-term therapeutic effects." #ASGCT2025 #CRISPR @ChildrensPhila Watch: https://hubs.li/Q03nZwnY0 https://hubs.li/Q03nZwnY0"
X Link 2025-05-23T20:30Z [---] followers, [--] engagements

"This Fourth of July we honor the relentless pursuit of progress that transforms patient care and shapes the future of medicine. Wishing everyone a safe and inspiring holiday. #FourthofJuly #IndependenceDay"
X Link 2025-07-04T15:00Z [---] followers, [--] engagements

"In light of the clearances @Solid_Bio plans to launch a phase 1b clinical trial in the final quarter of this year. #genetherapy #CPVT #CardiologyTwitter Read more: https://hubs.li/Q03wWsPg0 https://hubs.li/Q03wWsPg0"
X Link 2025-07-11T18:00Z [---] followers, [--] engagements

"Notably obe-cel has been approved in the United States since late [----]. #leusm #AcuteLymphoblasticLeukemia #CART #Autolus Read more: https://hubs.li/Q03yNG_00 https://hubs.li/Q03yNG_00"
X Link 2025-07-24T17:54Z [---] followers, [--] engagements

".@Sarepta noted that its partner @Roche provided additional context for the death pointing out that the physician who reported the death deemed it to be unrelated to #Elevidys. #genetherapy #Duchenne #MuscularDystrophy Read more: https://hubs.li/Q03z9-sN0 https://hubs.li/Q03z9-sN0"
X Link 2025-07-28T21:17Z [---] followers, [---] engagements

"The #genetherapy involves collection of blood-forming stem cells from bone marrow transduction of the cells with a lentiviral vector carrying NCF1 and reinfusion of the cells #ClinicalTrialsInProgress #ChronicGranulomatousDisease @GreatOrmondSt More: https://hubs.li/Q03DrFwb0 https://hubs.li/Q03DrFwb0"
X Link 2025-08-19T18:55Z [---] followers, [--] engagements

"ICYMI: The #genetherapy involves collection of blood-forming stem cells from bone marrow transduction of the cells with NCF1 via lentiviral vector and reinfusion of the cells #ClinicalTrialsInProgress #ChronicGranulomatousDisease @GreatOrmondSt More: https://hubs.li/Q03DLMlG0 https://hubs.li/Q03DLMlG0"
X Link 2025-08-20T23:30Z [---] followers, [--] engagements

"We showed that we can see a really durable effect with a single administration of ABO-101 out to a year and also in juvenile mice through their development into adults. - Tia DiTommaso PhD (@arbortx) #ASGCT2025 #PH1 #hyperoxaluria Watch: https://hubs.li/Q03GBKTh0 https://hubs.li/Q03GBKTh0"
X Link 2025-09-03T00:30Z [---] followers, [--] engagements

"ICYMI: We showed that we can see a really durable effect with a single administration of ABO-101 out to a year and also in juvenile mice through their development into adults. - Tia DiTommaso PhD (@arbortx) #ASGCT2025 #PH1 #hyperoxaluria Watch: https://hubs.li/Q03H6qCM0 https://hubs.li/Q03H6qCM0"
X Link 2025-09-05T19:00Z [---] followers, [--] engagements

"ICYMI: We've learned a lot from this program about analyzing both the on-target and off-target safety of our products and we'll extend that into our next products in the CNS realm and beyond. -John Murphy PhD (@arbortx) #ASGCT #PH1 #genetherapy Read: https://hubs.li/Q03HhVvb0 https://hubs.li/Q03HhVvb0"
X Link 2025-09-08T14:30Z [---] followers, [--] engagements

"In honor of #DuchenneActionMonth and #WorldDuchenneDay observed annually in September CGTLive took a look back at recent news in gene and cell therapy for #Duchenne. #MuscularDystrophy #DMD Read more: https://hubs.ly/Q03JFD0Z0 https://hubs.ly/Q03JFD0Z0"
X Link 2025-09-16T20:10Z [---] followers, [--] engagements

"ICYMI: In honor of #DuchenneActionMonth and #WorldDuchenneDay observed annually in September CGTLive took a look back at recent news in gene and cell therapy for #Duchenne. #MuscularDystrophy #DMD Read more: https://hubs.li/Q03KbYBc0 https://hubs.li/Q03KbYBc0"
X Link 2025-09-20T00:00Z [---] followers, [--] engagements

"The therapy is currently being evaluated in a first-in-human phase 1/2 clinical trial (NCT06844214). #genetherapy #myotonicdystrophy #SteinertsDisease @Sanofi Read more: https://hubs.li/Q03Lc_PT0 https://hubs.li/Q03Lc_PT0"
X Link 2025-09-26T19:59Z [---] followers, [---] engagements

"ICYMI: The therapy is currently being evaluated in a first-in-human phase 1/2 clinical trial (NCT06844214). #genetherapy #myotonicdystrophy #SteinertsDisease @Sanofi Read more: https://hubs.li/Q03LDwmw0 https://hubs.li/Q03LDwmw0"
X Link 2025-10-01T00:00Z [---] followers, [--] engagements

"ICYMI: In honor of #RareCancerDay observed annually on September [--] CGTLive is looking back at a collection of some of the news from the past few months focused on #celltherapy for #rarecancer indications. Read more: https://hubs.li/Q03M044S0 https://hubs.li/Q03M044S0"
X Link 2025-10-02T20:34Z [---] followers, [--] engagements

"RGX-314 @REGENXBIOs investigational gene therapy for wet age-related macular degeneration (AMD) was well-tolerated and reduced treatment burden in participants treated in the phase [--] AAVIATE trial (NCT04514653). Read more: http://ow.ly/ZsEw50L1k0a http://ow.ly/ZsEw50L1k0a"
X Link 2022-10-05T01:50Z [---] followers, [--] engagements

"RGX-314 REGENXBIOs investigational gene therapy for wet age-related macular degeneration (AMD) was well-tolerated and reduced treatment burden in participants treated in the phase [--] AAVIATE trial (NCT04514653). http://ow.ly/3vmP50L1zAz http://ow.ly/3vmP50L1zAz"
X Link 2022-10-05T20:10Z [---] followers, [--] engagements

"The RGX-314 gene therapy (@REGENXBIO) improved disease severity in patients with diabetic retinopathy (DR) according to new data from the phase 1/2 ALTITUDE study (NCT04567550). Read more: http://ow.ly/vHea50Lu0Om http://ow.ly/vHea50Lu0Om"
X Link 2022-11-04T11:00Z [---] followers, [--] engagements

"The FDA has accepted Athersys proposed modifications to its phase [--] MASTERS-2 clinical trial (NCT03545607) evaluating the cell therapy MultiStem (invimestrocel) for the treatment of ischemic stroke during a Type B meeting convened in late March. http://ow.ly/Tq8V50Nzk4Z http://ow.ly/Tq8V50Nzk4Z"
X Link 2023-04-04T18:15Z [---] followers, [--] engagements

"Freeline Therapeutics also announced that it would be cutting 30% of its workforce. #genetherapy Read more: http://ow.ly/pcv150NF9EP http://ow.ly/pcv150NF9EP"
X Link 2023-04-10T16:56Z [---] followers, [--] engagements

"Approximately [---] patients will be enrolled in cohort [--] of the double-blind placebo-controlled MATRICS-1 study (NCT04533464) evaluating invimestrocel (MultiStem; @athersys). #celltherapy #HemorrhagicTrauma Read more: https://ow.ly/L0TN50P9UbN https://ow.ly/L0TN50P9UbN"
X Link 2023-07-12T18:58Z [---] followers, [--] engagements

". @athersys has begun patient enrollment in the third and final cohort of its phase [--] MATRICS-1 study (NCT04533464) evaluating invimestrocel (MultiStem) #celltherapy for the potential treatment of patients following resuscitation from hemorrhagic trauma. https://ow.ly/5BfG50Pa7Y1 https://ow.ly/5BfG50Pa7Y1"
X Link 2023-07-13T15:55Z [---] followers, [--] engagements

"ICYMI: Approximately [---] patients will be enrolled in cohort [--] of the double-blind placebo-controlled MATRICS-1 study (NCT04533464) evaluating invimestrocel (MultiStem; @athersys). #celltherapy #HemorrhagicTrauma Read more: https://ow.ly/L0TN50P9UbN https://ow.ly/L0TN50P9UbN"
X Link 2023-07-14T23:40Z [---] followers, [--] engagements

"@ArtivaBio noted no allogeneic NK or CAR-T therapy has previously received IND clearance for evaluation in an autoimmune disease indication. #SystemicLupusErythematosus #lupus #NKcell #celltherapy More: https://ow.ly/jBqP50PB4fn https://ow.ly/jBqP50PB4fn"
X Link 2023-08-19T11:05Z [---] followers, [--] engagements

"Dr. Ahmad Masri discusses the evolving landscape of care for ATTR #Amyloidosis the promise of gene therapy and NTLA-2001. https://www.cgtlive.com/view/ahmad-masri-potential-gene-therapy-attr-amyloidosis https://www.cgtlive.com/view/ahmad-masri-potential-gene-therapy-attr-amyloidosis"
X Link 2023-10-29T01:15Z [---] followers, [--] engagements

"Just like Dr. @VietHeartPA we've had our eyes on these approaches in cardiology this year Check out our recent coverage of both of these exciting approaches below. VERVE-101: NTLA-2001: https://www.cgtlive.com/view/intellia-s-crispr-therapy-attr-cm-first-late-stage-trials-ntla-2001 https://www.cgtlive.com/view/crispr-editing-therapy-verve-101-reduces-ldl-c-small-trial-familial-hypercholesteremia @VietHeartPA talked up a major win in #cardiology other than semaglutide: CRISPR-Cas9 and the VERVE-101 & NTLA-2001 trial data. Gene therapy is making advances. https://t.co/gnlSTirEq1"
X Link 2023-12-01T19:01Z [---] followers, [--] engagements

"BCMA-directed CAR T-cell therapy anitocabtagene autoleucel demonstrated a 76% complete remission rate and 89% negative minimal residual disease in patients with relapsed/refractory multiple myeloma. #ASH23 #mmsm https://www.cgtlive.com/view/novel-bcma-directed-anito-cel-highly-effective-for-myeloma https://www.cgtlive.com/view/novel-bcma-directed-anito-cel-highly-effective-for-myeloma"
X Link 2023-12-12T16:56Z [---] followers, [---] engagements

"Anito-cel (@arcellx) utilizes novel CAR T cell technology compared with other agents with a smaller D-Domain binder. #celltherapy #mmsm #MultipleMyeloma #ASH23 Read more: https://www.cgtlive.com/view/novel-bcma-directed-anito-cel-highly-effective-for-myeloma https://www.cgtlive.com/view/novel-bcma-directed-anito-cel-highly-effective-for-myeloma"
X Link 2023-12-12T18:58Z [---] followers, [---] engagements

"ICYMI: Anito-cel (@arcellx) utilizes novel CAR T cell technology compared with other agents with a smaller D-Domain binder. #celltherapy #mmsm #MultipleMyeloma #ASH23 Read more: https://www.cgtlive.com/view/novel-bcma-directed-anito-cel-highly-effective-for-myeloma https://www.cgtlive.com/view/novel-bcma-directed-anito-cel-highly-effective-for-myeloma"
X Link 2023-12-14T02:55Z [---] followers, [---] engagements

"Further research is needed to determine if cell therapy may be beneficial to certain subgroups of patients. #Stroke #CellTherapy https://www.cgtlive.com/view/multistem-cell-therapy-not-superior-to-placebo-ischemic-stroke https://www.cgtlive.com/view/multistem-cell-therapy-not-superior-to-placebo-ischemic-stroke"
X Link 2024-01-16T22:20Z [---] followers, [--] engagements

"New interim clinical data on @REGENXBIO's RGX-202 gene therapy for #Duchenne presented at #MDAconference. Read about the biomarker findings now. #MDA2024 #MDA24 https://www.cgtlive.com/view/rgx-202-gene-therapy-reduces-ck-yields-detectable-microdystrophin-in-patients-with-dmd https://www.cgtlive.com/view/rgx-202-gene-therapy-reduces-ck-yields-detectable-microdystrophin-in-patients-with-dmd"
X Link 2024-03-04T23:17Z [---] followers, [---] engagements

"The treatment is an investigational single-use AAV therapeutic developed by REGENXBIO that utilizes the companys NAV AAV8 vector to deliver microdystrophin. #AANAM #MuscularDystrophy @REGENXBIO Read more: https://www.cgtlive.com/view/rgx-202-well-tolerated-multiple-doses-among-dmd https://www.cgtlive.com/view/rgx-202-well-tolerated-multiple-doses-among-dmd"
X Link 2024-04-17T17:20Z [---] followers, [--] engagements

"ICYMI: The treatment is an investigational single-use AAV therapeutic developed by REGENXBIO that utilizes the companys NAV AAV8 vector to deliver microdystrophin. #AANAM #MuscularDystrophy @REGENXBIO Read more: https://www.cgtlive.com/view/rgx-202-well-tolerated-multiple-doses-among-dmd https://www.cgtlive.com/view/rgx-202-well-tolerated-multiple-doses-among-dmd"
X Link 2024-04-19T17:20Z [---] followers, [---] engagements

"AlloNK which is intended to heighten the B-cell depleting effect of the monoclonal antibodies via antibody-dependent cellular cytotoxicity (ADCC) is unengineered. #lupus #celltherapy @ArtivaBio Read more: https://www.cgtlive.com/view/artiva-biotherapeutics-doses-first-patient-nk-cell-therapy-allonk-lupus-trial https://www.cgtlive.com/view/artiva-biotherapeutics-doses-first-patient-nk-cell-therapy-allonk-lupus-trial"
X Link 2024-04-25T19:05Z [---] followers, [--] engagements

"Lawrence R. Lustig MD discussed promising early results from the phase 1/2 CHORD trial evaluating Decibel Therapeutics and Regenerons DB-OTO for hearing loss. #ASGCT24 https://www.cgtlive.com/view/otoferlin-related-hearing-loss-gene-therapy-open-door-gene-therapies-other-types-hearing-loss https://www.cgtlive.com/view/otoferlin-related-hearing-loss-gene-therapy-open-door-gene-therapies-other-types-hearing-loss"
X Link 2024-05-20T00:17Z [---] followers, [---] engagements

"The new cohort which is open to ambulatory boys with DMD will seek to enroll up to [--] participants aged [--] to [--] years old. #Duchenne #MuscularDystrophy #genetherapy @REGENXBIO Read more: https://www.cgtlive.com/view/regenxbio-evaluate-duchenne-muscular-dystrophy-gene-therapy-rgx-202-patients-aged-1-3-years-old https://www.cgtlive.com/view/regenxbio-evaluate-duchenne-muscular-dystrophy-gene-therapy-rgx-202-patients-aged-1-3-years-old"
X Link 2024-06-27T16:46Z [---] followers, [--] engagements

"The patients received [---] mg/kg of NTLA-2001 which led to an expected lower-than-targeted 52% median reduction in serum TTR by day [--]. #CRISPR #amyloidosis @intelliatx Read more: https://www.cgtlive.com/view/intellia-successfully-redoses-crispr-gene-editing-therapy-ntla-2001 https://www.cgtlive.com/view/intellia-successfully-redoses-crispr-gene-editing-therapy-ntla-2001"
X Link 2024-06-28T01:55Z [---] followers, [--] engagements

"ICYMI: The new cohort which is open to ambulatory boys with DMD will seek to enroll up to [--] participants aged [--] to [--] years old. #Duchenne #MuscularDystrophy #genetherapy @REGENXBIO Read more: https://www.cgtlive.com/view/regenxbio-evaluate-duchenne-muscular-dystrophy-gene-therapy-rgx-202-patients-aged-1-3-years-old https://www.cgtlive.com/view/regenxbio-evaluate-duchenne-muscular-dystrophy-gene-therapy-rgx-202-patients-aged-1-3-years-old"
X Link 2024-06-28T13:10Z [---] followers, [--] engagements

"ICYMI: The patients received [---] mg/kg of NTLA-2001 which led to an expected lower-than-targeted 52% median reduction in serum TTR by day [--]. #CRISPR #amyloidosis @intelliatx Read more: https://www.cgtlive.com/view/intellia-successfully-redoses-crispr-gene-editing-therapy-ntla-2001 https://www.cgtlive.com/view/intellia-successfully-redoses-crispr-gene-editing-therapy-ntla-2001"
X Link 2024-06-28T21:45Z [---] followers, [--] engagements

"4D-710 4D Molecular Therapeutics (4DMT)gene therapy candidate for treating cystic fibrosis (CF) has demonstrated CFTR transgene RNA and protein expression in patients with cystic fibrosis. https://www.cgtlive.com/view/low-dose-gene-therapy-well-tolerated-trends-improvement-cystic-fibrosis https://www.cgtlive.com/view/low-dose-gene-therapy-well-tolerated-trends-improvement-cystic-fibrosis"
X Link 2024-07-15T01:53Z [---] followers, [---] engagements

"4D Molecular Therapeutics anticipates that it will provide an update on the program at some point in [----]. #Fabry #FabryDisease #genetherapy Read more: https://www.cgtlive.com/view/fda-lifts-clinical-hold-trial-4d-molecular-therapeutics-fabry-disease-gene-therapy-4d-310 https://www.cgtlive.com/view/fda-lifts-clinical-hold-trial-4d-molecular-therapeutics-fabry-disease-gene-therapy-4d-310"
X Link 2024-08-12T20:50Z [---] followers, [--] engagements

"ICYMI: 4D Molecular Therapeutics anticipates that it will provide an update on the program at some point in [----]. #Fabry #FabryDisease #genetherapy Read more: https://www.cgtlive.com/view/fda-lifts-clinical-hold-trial-4d-molecular-therapeutics-fabry-disease-gene-therapy-4d-310 https://www.cgtlive.com/view/fda-lifts-clinical-hold-trial-4d-molecular-therapeutics-fabry-disease-gene-therapy-4d-310"
X Link 2024-08-16T01:55Z [---] followers, [--] engagements

"PROACT [--] which is a randomized blinded sham controlled study is expected to enroll around [---] patients in total. #diabetes #ChronicKidneyDisease #Type2Diabetes @ProKidney Read more: https://www.cgtlive.com/view/prokidney-focus-us-trial-t2d-ckd-cell-therapy-rilparencel https://www.cgtlive.com/view/prokidney-focus-us-trial-t2d-ckd-cell-therapy-rilparencel"
X Link 2024-09-12T21:02Z [---] followers, [--] engagements

"ICYMI: PROACT [--] which is a randomized blinded sham controlled study is expected to enroll around [---] patients in total. #diabetes #ChronicKidneyDisease #Type2Diabetes @ProKidney Read more: https://www.cgtlive.com/view/prokidney-focus-us-trial-t2d-ckd-cell-therapy-rilparencel https://www.cgtlive.com/view/prokidney-focus-us-trial-t2d-ckd-cell-therapy-rilparencel"
X Link 2024-09-14T01:55Z [---] followers, [--] engagements

"P-BCMA-ALLO1 is the subject of a strategic collaboration agreement between @PoseidaThera and @Roche that was established in [----]. #mmsm #MultipleMyeloma #celltherapy Read more: https://www.cgtlive.com/view/poseida-therapeutics-garners-fda-rmat-designation-allogeneic-car-t-p-bcma-allo1-multiple-myeloma https://www.cgtlive.com/view/poseida-therapeutics-garners-fda-rmat-designation-allogeneic-car-t-p-bcma-allo1-multiple-myeloma"
X Link 2024-09-19T20:47Z [---] followers, [--] engagements

"ICYMI: In September BridgeBio and Poseida Therapeutics Inc. garnered RMAT designations for their respective products. #genetherapy #celltherapy Read more: https://www.cgtlive.com/view/fda-activity-recap-september-2024-features-acute-lymphoblastic-leukemia-trial-clearance-multiple-rmat-designations https://www.cgtlive.com/view/fda-activity-recap-september-2024-features-acute-lymphoblastic-leukemia-trial-clearance-multiple-rmat-designations"
X Link 2024-10-02T14:50Z [---] followers, [--] engagements

"Last month saw data updates from @REGENXBIO @biogen and more. #celltherapy #genetherapy Read more: https://www.cgtlive.com/view/data-roundup-september-2024-features-updates-ophthalmology-gene-therapy-car-t-lymphoma-more https://www.cgtlive.com/view/data-roundup-september-2024-features-updates-ophthalmology-gene-therapy-car-t-lymphoma-more"
X Link 2024-10-04T21:05Z [---] followers, [--] engagements

"ICYMI: Last month saw data updates from @REGENXBIO @biogen and more. #celltherapy #genetherapy Read more: https://www.cgtlive.com/view/data-roundup-september-2024-features-updates-ophthalmology-gene-therapy-car-t-lymphoma-more https://www.cgtlive.com/view/data-roundup-september-2024-features-updates-ophthalmology-gene-therapy-car-t-lymphoma-more"
X Link 2024-10-05T22:05Z [---] followers, [--] engagements

"In the substudy ABBV-RGX-314 was administered to patients subretinally at a dose of 1.3x1011 GC/eye about [--] year or more after they had previously received the gene therapy in their other eye. #wetAMD #genetherapy #Ophthalmology @REGENXBIO Read more: https://www.cgtlive.com/view/regenxbio-abbv-rgx-314-reduces-need-antivegf-injections-application-fellow-eyes-patients-wet-amdutm_source=twitter&utm_medium=social&utm_campaign=492f9250-deb0-401f-8804-d9c643c48d4f"
X Link 2024-10-22T23:10Z [---] followers, [--] engagements

"ICYMI: ABBV-RGX-314 was administered to patients subretinally at a dose of 1.3x1011 GC/eye about [--] year or more after they had previously received the gene therapy in their other eye. #wetAMD #genetherapy #Ophthalmology @REGENXBIO More: https://www.cgtlive.com/view/regenxbio-abbv-rgx-314-reduces-need-antivegf-injections-application-fellow-eyes-patients-wet-amdutm_source=twitter&utm_medium=social&utm_campaign=48372272-98ee-4937-9c45-66c68be4aa18"
X Link 2024-10-23T23:45Z [---] followers, [--] engagements

".@REGENXBIO anticipates that it will submit a biologics license application for RGX-202 in [----] via an accelerated approval pathway. #genetherapy #MuscularDystrophy #Duchenne Read more: https://www.cgtlive.com/view/regenxbio-doses-first-patient-phase-trial-dmd-gene-therapy-rgx-202 https://www.cgtlive.com/view/regenxbio-doses-first-patient-phase-trial-dmd-gene-therapy-rgx-202"
X Link 2024-12-03T20:03Z [---] followers, [---] engagements

"ICYMI: @REGENXBIO anticipates that it will submit a biologics license application for RGX-202 in [----] via an accelerated approval pathway. #genetherapy #MuscularDystrophy #Duchenne Read more: https://www.cgtlive.com/view/regenxbio-doses-first-patient-phase-trial-dmd-gene-therapy-rgx-202 https://www.cgtlive.com/view/regenxbio-doses-first-patient-phase-trial-dmd-gene-therapy-rgx-202"
X Link 2024-12-04T23:05Z [---] followers, [---] engagements

"@REGENXBIO Doses First Patient in Phase [--] Trial for #DMD @RocketPharma's Gene Therapy RP-A501 Shows Promising Phase [--] Results in #DanonDisease Review more top news and interview highlights in #celltherapy and #genetherapy from the week ending Dec 6: https://www.cgtlive.com/view/cgtlive-weekly-rewind-december-6-2024 https://www.cgtlive.com/view/cgtlive-weekly-rewind-december-6-2024"
X Link 2024-12-06T20:09Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing